Alabama is currently home to 1235 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
TSC Biosample Repository and Natural History Database
NCT05676099
Recruiting
The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document the impact of the disease on a person's health over his or her lifetime. This data may be collected retrospectively or prospectively.
Gender:
ALL
Ages:
All
Trial Updated:
10/15/2024
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Tuberous Sclerosis, Lymphangioleiomyomatosis
Register for Updates
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT02977780
Recruiting
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib * Temozolomide (temodar) * Neratinib * CC115 * QBS10072S
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Glioblastoma
Register for Updates
Prenatal Behavioral Intervention to Prevent Maternal Cytomegalovirus (CMV) in Pregnancy
NCT04615715
Recruiting
This study will evaluate whether a brief prenatal clinic-based cytomegalovirus (CMV) risk-reduction behavioral intervention will prevent maternal CMV infections during pregnancy in women.
Gender:
FEMALE
Ages:
Between 14 years and 39 years
Trial Updated:
10/14/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Maternal Cytomegalovirus Infections, Cytomegalovirus Congenital
Register for Updates
The Fit with Us Study
NCT06207084
Recruiting
The purpose of this 32 week study is to use an innovative experimental design known as SMART (Sequential Multiple Assignment Randomized Trial), which will allow us to determine the best way to sequence the delivery of teleexercise (referred to as an adaptive intervention), combined with predictive analytics on participant adherence in a stepped program of physical activity interventions. All 257 participants will have access to a library of recorded video exercise content, and a weekly wellness... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
10/11/2024
Locations: Wellness, Health and Research Facility, Birmingham, Alabama
Conditions: Mobility Limitations, Disability Physical, Telehealth, Health Coaching, Physical Activity, Behavior, Health, eHealth, Health Literacy, Self Efficacy, Fatigue, Usability, Predictive Model
Register for Updates
Allopurinol Improves Heart Function in African Americans With Resistant Hypertension
NCT05888233
Recruiting
African American adults in the United States have the highest prevalence rate of high blood pressure (hypertension) and heart failure in the world. African Americans with treatment resistant hypertension have higher levels of the enzyme - xanthine oxidase compared to Caucasians. This trial will test if administration of the xanthine oxidase inhibitor - Allopurinol (commonly used in the treatment of gout), given over a period of 8 weeks, will improve heart function, exercise ability and quality o... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/11/2024
Locations: Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama
Conditions: Heart Failure Preserved Ejection Fraction, Resistant Hypertension
Register for Updates
Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy
NCT01429389
Recruiting
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Down Syndrome, Fetal Aneuploidy
Register for Updates
A Motion Exergaming Approach for Symptom Management: HNC
NCT04632654
Recruiting
This overall objective of the RCT is to test an intervention to overcome the PA barriers for head and neck cancer (HNC) patients during the first 6 months after their treatment. PAfitME stands for a personalized Physical Activity intervention with fitness graded Motion Exergames. PAfitME is delivered via a tested mix of FaceTime calls and home visits, uses commercially available exergaming platforms (Nintendo Switch). We propose the following specific aims: (1) When compared to an attention cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Head and Neck Cancer
Register for Updates
Impella RP Flex with Smart Assist
NCT06637644
Recruiting
To capture observational data of the Abiomed Impella RP Flex in a real-world setting.
Gender:
ALL
Ages:
All
Trial Updated:
10/09/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Right Ventricular (RV) Dysfunction
Register for Updates
Longitudinal TSPO PET Imaging with [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
NCT06289582
Recruiting
The overall goal of this protocol is to investigate \[18F\]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in \[18F\]DPA-714 binding in PD participants during a 24-month interval. Primary Objectives * To compare \[18F\]DPA-714 binding in prodromal and manifest PD and healthy volunteers. * To determine the longitudinal change in \[18F\]DPA-714 during a 24-month interval for prodromal and early initially untreated PD... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/08/2024
Locations: UAB, Birmingham, Alabama
Conditions: Parkinson Disease
Register for Updates
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
NCT04362644
Recruiting
The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
10/08/2024
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
NCT03809351
Recruiting
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study. Assessment of interactions between race and vascular risk factors, brain tau levels measured with AV-1451-PET, and cogn... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
10/08/2024
Locations: UAB, Birmingham, Alabama
Conditions: Alzheimer Disease
Register for Updates
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
NCT03503331
Recruiting
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \[C-11\]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \[C-11\]PiB-PET, and cognitive status will be the primary outcome of this imaging study.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
10/08/2024
Locations: University of Alabama at Birmingham Medical Center, Birmingham, Alabama
Conditions: Alzheimer Disease
Register for Updates